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The majority of cutaneous squamous cell carcinomas can 
be cured with surgical excision but a small subset of these 
tumours metastasize. Our aim was to determine the rate of 
local recurrences and metastasis of these tumours in a pa-
tient cohort in Finland. Overall, 4.2% of the 1,131 tumours 
were metastatic and 2.2% of the tumours had a local recur-
rence. Over half of metastases were found within 3 months 
after tumour diagnosis. Patients with cutaneous squamous 
cell carcinomas should undergo individualised risk ascer-
tainment and in high risk cases monitoring should be orga-
nised especially during the first years after diagnosis.
Recognising patients with high risk cutaneous squa-
mous cell carcinomas is essential in planning effective 
monitoring. The aim of this study was to determine the 
rate of local recurrences and metastases of cutaneous 
squamous cell carcinomas in a previously defined pa-
tient cohort in Finland. Pathology database search was 
performed to identify cutaneous squamous cell carci-
noma patients and their medical records were revie-
wed. The cohort consisted of 774 patients with 1,131 
cutaneous squamous cell carcinoma tumours. Overall, 
4.2% (48/1,131) of the tumours were metastatic and 
2.2% (25/1,131) had a local recurrence. Three of the 
metastatic tumours and 8 of the recurrent tumours 
had an invasion depth of ≤ 2 mm. The majority of me-
tastases (28/48; 58%) were found within 3 months 
of the diagnosis of cutaneous squamous cell carcino-
ma. In conclusion, our study demonstrated recurren-
ces and metastases even in the case of thin cutaneous 
squamous cell carcinomas and in high-risk cases close 
monitoring should be organised during the first years 
after diagnosis.
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The incidence of cutaneous squamous cell carcinoma (cSCC) is increasing throughout the world (1). 
Although the vast majority of cSCCs can be cured with 
surgical excision, the rate of metastasis in cSCC has been 
estimated to range from 2% to 5% (2–5) and metastatic 
disease has a poor prognosis with a median survival 
of less than 2 years (2, 6). It is therefore important to 
recognise patients and tumours with high risk features 
early and effectively. We have previously reported trends 
in cSCC in a patient cohort in Finland over a 10-year 
study period (7). The objective of this present study 
was to determine the rate of local recurrences and me-
tastases of cSCC in the same cohort and to analyse the 
histopathological features of the tumours together with 
patient characteristics, including any history of prema-
lignant lesions, basal cell carcinoma (BCC) or cutaneous 
melanoma (CM). 
MATERIALS AND METHODS
A pathology database search was performed at Fimlab Labora-
tories to identify all patients in the Pirkanmaa region of Finland 
diagnosed with cSCC in 2006–2015. Details of these patients and 
their tumours were obtained by reviewing the clinical records 
of Tampere University Hospital. The data on the cSCC tumours 
included anatomic location, degree of differentiation and depth of 
invasion. Patients with multiple primary cSCC tumours diagnosed 
during the given period were included, and each tumour was ana-
lysed separately. The age of the patient at diagnosis of the primary 
tumour, gender and possible immunosuppression were recorded. 
The lifetime prevalence of actinic keratosis (AK), cSCC in situ, 
i.e. Bowen’s disease (BD), BCC and CM were ascertained for each 
patient from the medical records. The timing of the diagnosis of 
each local recurrence or metastasis of cSCC occurring within the 
period concerned was determined. In the case of multiple cSCCs, 
one primary tumour was designated as the recurrent or metastatic 
cSCC on the basis of the clinical notes. This retrospective study 
was approved by the institutional review board of Tampere Uni-
versity Hospital, Finland.
Categorical data were described in terms of the number of 
patients or number of tumours with percentages, and differences 
between such variables were tested with the Pearson chi-square 
test or Fisher’s exact test. All the analyses were conducted using 
IBM SPSS Statistics version 25.0 software (IBM SPSS, Chicago, 
IL, USA), and p-values under 0.05 were considered statistically 
significant.
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The cohort consisted of 774 patients with 1,131 cSCC 
tumours. Altogether, 25 of the 774 patients (3.2%) had 
a recurrent cSCC. Tumours in the location of the scalp 
and neck (4 recurrences in 91 tumours; 4.4% of cases in 
that location) or the trunk (2 recurrences in 61 tumours; 
3.3%) showed more recurrences than would be expected 
in view of the overall recurrence rate (25 recurrences in 
1,131 tumours; 2.2%), whereas only one recurrence was 
found in the case of the 106 tumours located on the ear 
(0.9%) (Table I). Nine out of the 25 recurrent tumours 
(36.0%) were well differentiated and 8 (32.0%) had 
an invasion depth of ≤ 2 mm (Table I). Five recurrent 
tumours had metastasized: 3 located on the face, one on 
the lip and one on the scalp. The median recurrence time 
was 13 months (range 2–72 months). 
Metastatic tumours
Of the 774 patients, 48 (6.2%) had a metastatic cSCC (Ta-
ble I), including 21 patients (43.8%) who had a history of 
premalignant lesions, whereas 538 out of the 726 patients 
without any metastasis (74.1%) had had a premalignant 
lesion (p < 0.001). A total of 27.1% (13/48) of patients 
with a metastatic cSCC had BCC, compared with 41.7% 
(303/726) of those without any metastasis (p = 0.049). 
Any specific immunosuppression type (heart, kidney 
or liver transplantation, rheumatoid arthritis, chronic 
leukaemia or lymphoma) was not associated with meta-
static cSCC. Altogether, 4.2% of the tumours (48/1,131) 
were metastatic, including 5 out of the 91 tumours on 
the scalp and neck (5.5%) but only 
one out of the 136 (0.7%) on an upper 
extremity (Table I). The majority of the 
metastatic tumours were moderately or 
poorly differentiated (41/48; 85.4%), 
and 3 (6.3%) had an invasion depth of 
≤ 2 mm (Table I). The median time for 
the observation of a metastasis was 4 
months (range 0–34 months), with 58% 
of them (28/48) found within 3 months 
of the cSCC diagnosis.
DISCUSSION
The proportion of the 1,131 cSCC 
tumours that were metastatic, 4.2%, 
is in line with previously reported me-
tastasis rates of between 2% to 5% in 
cSCC (2–5). High-risk prognostic fac-
tors for cSCC include tumour location 
on the ear, lip or areas of long-lasting 
inflammation, a tumour diameter of 
> 2 cm, a histological depth of > 6 mm, 
moderately or poorly differentiated 
grade, certain histological subtypes 
(acantholytic, spindle, desmoplastic), 
perineural invasion, recurrence and 
immunosuppression (2). According to 
a recent meta-analysis, tumour depth 
is associated with the highest risk of 
local recurrence and metastasis in cases 
of cSCC (8). In our study, 6.3% of the 
metastatic tumours had an invasion 
depth of ≤ 2 mm, although tumours of 
that thickness have been considered 
to entail only a minimal risk (2). One 
previous study, for instance, states that 
no cSCC tumours ≤ 2 mm in thickness 
generated metastases (9).
Table I. Characteristics of patients with recurrent cutaneous squamous cell carcinoma 
(cSCC) (n = 25; 3.2% of 774), recurrent cSCC tumours (n = 25; 2.2% of 1,131), patients 














Patients n = 25 n = 749 n = 48 n = 726
Sex 0.840 0.103
  Men 12 (48.0) 382 (51.0) 30 (62.5) 364 (50.1)
  Women 13 (52.0) 367 (49.0) 18 (37.5) 362 (49.9)
Age 0.865 0.151
  < 60 years 0 (0) 35 (4.7) 4 (8.3) 31 (4.3)
  60–69 years 2 (8.0) 82 (11.0) 9 (18.8) 75 (10.3)
  70–79 years 10 (40.0) 228 (30.4) 12 (25.0) 226 (31.1)
  80–89 years 10 (40.0) 313 (41.8) 16 (33.3) 307 (42.3)
  ≥ 90 years   3 (12.0)   91 (12.1)   7 (14.6)   87 (12.0)
Immunosuppression 1.000 1.000
  No 23 (92.0) 670 (89.5) 43 (89.6) 650 (89.5)
  Yes 2 (8.0)   79 (10.5)   5 (10.4)   76 (10.5)
Actinic keratosis/Bowen’s disease 0.165 < 0.001
  No 10 (40.0) 205 (27.4) 27 (56.3) 188 (25.9)
  Yes 15 (60.0) 544 (72.6) 21 (43.8) 538 (74.1)
Basal cell carcinoma 0.837 0.049
  No 14 (56.0) 444 (59.3) 35 (72.9) 423 (58.3)
  Yes 11 (44.0) 305 (40.7) 13 (27.1) 303 (41.7)
Cutaneous melanoma 0.673 0.357
  No 23 (92.0) 701 (93.6) 47 (97.9) 677 (93.3)
  Yes   2 (8.0)   48 (6.4)   1 (2.1)   49 (6.7)
Tumours n = 25 n = 1,106 n = 48 n = 1,083
Tumour location 0.271 < 0.001
  Lip 2 (8.0) 50 (4.5) 3 (6.3) 49 (4.5)
  Eyelid 0 (0) 11 (1.0) 1 (2.1) 10 (0.9)
  Ear 1 (4.0) 105 (9.5) 4 (8.3) 102 (9.4)
  Face 9 (36.0) 555 (50.2) 17 (35.4) 547 (50.5)
  Scalp and neck 4 (16.0) 87 (7.9) 5 (10.4) 86 (7.9)
  Trunk 2 (8.0) 59 (5.3) 1 (2.1) 60 (5.5)
  Upper extremity 3 (12.0) 133 (12.0) 1 (2.1) 135 (12.5)
  Lower extremity 2 (8.0) 66 (6.0) 2 (4.2) 66 (6.1)
  Anogenital area 1 (4.0) 30 (2.7) 9 (18.8) 22 (2.0)
  Oral cavity 1 (4.0) 10 (0.9) 5 (10.4)   6 (0.6)
Tumour differentiation 0.130 < 0.001
  Well 9 (36.0) 512 (46.3) 6 (12.5) 515 (47.6)
  Moderately 9 (36.0) 441 (39.9) 27 (56.3) 423 (39.1)
  Poorly 5 (20.0)   84 (7.6) 14 (29.2) 75 (6.9)
  Unknown 2 (8.0)   69 (6.2) 1 (2.1) 70 (6.5)
Invasion depth 0.173 < 0.001
  < 1 mm 1 (4.0)   44 (4.0) 0 (0) 45 (4.2)
  1.0–2.0 mm 7 (28.0) 306 (27.7) 3 (6.3) 310 (28.6)
  2.1.0–4.0 mm 1 (4.0) 202 (18.3) 3 (6.3) 200 (18.5)
  > 4.0 mm 5 (20.0) 107 (9.7) 15 (31.3)   97 (9.0)
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The rate of local recurrences per tumour in the present 
series, 2.2%, is slightly lower than the figures of 2.7% 
(5) and 3.2% (10) reported previously. It should be re-
membered, however, that the recurrence rate depends 
on the subset of patients, the follow-up period and the 
treatment methods. In a systematic review, the pooled 
average of the local recurrences after standard surgical 
excision was 5.4% (11). Approximately one third of the 
recurrent tumours in our study were well differentiated 
and had an invasion depth of ≤ 2 mm, which are gene-
rally considered to be low-risk features (2). The risk of 
local recurrence has been reported to be dependent on 
increased tumour thickness (9, 12), tumour diameter (12) 
and desmoplasia (9). 
Surprisingly many of the present scalp and neck cSCCs 
were recurrent and metastatic, and tumours on the trunk 
also showed more recurrences than was expected. On 
the other hand, recurrent tumours on the ear were rare. 
cSCCs located on the ears have been recognised as high-
risk tumours (2, 3), while the scalp and neck have been 
identified as an intermediate-risk area and the trunk and 
limbs as a low-risk area (3). The status of cSCCs located 
on the trunk could be attributable to a lack of information, 
however, as these are infrequent compared with cSCCs 
of the head and neck. The guidelines contained in the 
8th edition of the American Joint Committee on Cancer 
(AJCC) Staging Manual, for example, apply only to 
cSCCs of the head and neck (13). In addition, the wide 
diversity of cSCC histopathological subtypes could mean 
that the prognostic significance of some of them could 
be underestimated (13). 
Where the majority of our metastases (58%) were 
found within 3 months of the diagnosis of cSCC, pre-
vious studies have reported that 73% of metastases oc-
curred within the first year after resection (9) and all the 
metastases appeared within two years (14). There is no 
standardised follow-up schedule for patients with cSCC, 
but close monitoring has been recommended, particularly 
during the first years after diagnosis (2).
The fact that patients with metastatic cSCC had prema-
lignant lesions and BCC less frequently than those who 
had non-metastatic cSCC suggests that patients without 
a history of precursor lesions may have an increased 
risk of developing biologically more aggressive cSCC 
tumours with a distinct aetiopathogenesis. On the other 
hand, patients previously treated for premalignant lesions 
or BCC may be subject to increased surveillance for new 
skin tumours and have their cSCC detected and treated 
early, before progression to a metastatic tumour. 
In conclusion, our study demonstrated recurrences 
and metastases even in the case of thin cSCCs, with the 
majority of metastases being found within a few months 
of the cSCC diagnosis. Patients with cSCC should un-
dergo individualised risk assessment and in high-risk 
cases close monitoring should be organised during the 
first years after diagnosis.
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